BioSpace News Archive

LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology has published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes – one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.

Guardant Health introduces Guardant Galaxy TM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery.

Schrödinger today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a presentation on Tuesday, February 14, 2023, at 1:00 p.m. ET.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open.

9 Meters Biopharma, Inc. today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City.

Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd’s patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023, after the close of the market.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today 6-month interim data from human clinical experience in its REVITA-T2Di (T2Di) long-term open-label cohort.

Research indicates that NPTXR antibodies may have utility for treatment of gastro-intestinal cancers

ChromaDex Corp. announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu.